612
Participants
Start Date
March 27, 2012
Primary Completion Date
July 3, 2018
Study Completion Date
August 27, 2018
Rociletinib
Phase 1: Rociletinib \<900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
Rociletinib
Phase 1: Rociletinib 900 mg BID FB will be administered in escalating dosages in a period of 21-day cycles
Rociletinib
"Phase 1: Rociletinib 500 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 500 mg BID HBr will be administered daily"
Rociletinib
"Phase 1: Rociletinib 625 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 625 mg BID HBr will be administered daily"
Rociletinib
"Phase 1: Rociletinib 750 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 750 mg BID HBr will be administered daily"
Rociletinib
"Phase 1: Rociletinib 1000 mg BID HBr will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib 1000 mg BID HBr will be administered daily"
Chris O'Brien Lifehouse, Camperdown
Memorial Sloan Kettering Cancer Center, New York
Monter Cancer Center, Lake Success
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Cancer Institute (UPMC), Div. of Medical Oncology, Pittsburgh
Perelman Center for Advanced Medicine, Philadelphia
Georgetown University Hospital, Washington D.C.
University of Maryland, Baltimore
Virginia Cancer Specialists, PC, Fairfax
University Cancer & Blood Center, Athens
Florida Hospital Cancer Institute, Orlando
Sylvester Comprehensive Cancer Center/UMHC, Miami
Vanderbilt University, Nashville
Ohio State University, Comprehensive Cancer Center, Columbus
University of Cincinnati Medical Center, Cincinnati
Karmanos Cancer Care Institute, Detroit
University of Chicago Medical Center, The Duchossois Center for Advanced Medicine, Chicago
Tulsa Cancer Institute, Tulsa
MD Anderson Cancer Center, Houston
University of Colorado Anschutz Medical Campus, Aurora
Huntsman Cancer Institute, Salt Lake City
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles
Samuel Oschin Cancer Center, Los Angeles
UCLA Health System, Santa Monica
East Valley Hematology and Oncology Medical Group, Inc., Whittier
The Oncology Institute of Hope and Innovations, Whittier
City of Hope National Medical Center, Duarte
Compassionate Care Research Group, Inc., Fountain Valley
University of California, Irvine, Orange
Stanford Cancer Institute, Stanford
Institut Gustave Roussy, Villejuif
University of California Davis Medical Center, Sacramento
Providence CancerCenter Oncology and Hematology Care Clinic-Eastside Portland, Portland
Swedish Cancer Institute, Seattle
University of Washington, Seattle
Mass General Hospital, Boston
Dana Farber Cancer Institute, Boston
Saint Joseph Mercy Hospital, Ann Arbor
Regional Cancer Care Associates, Morristown
Regional Cancer Center, New Brunswick
University of Texas Southwestern Medical Center, Dallas
Peter MacCallum Cancer Centre, East Melbourne
Centre Hospitalier Universitaire de Grenoble, Grenoble
Centre Léon Bérard, Lyon
Centre François Baclesse, Caen
Centre Hospitalier Intercommunal Créteil, Créteil
Centre Hospitalier Régional Universitaire de Lille, Lille
Med University Gdansk, Gdansk
Centre Antoine Lacassagne, Nice
Lead Sponsor
Clovis Oncology, Inc.
INDUSTRY